ArticleFrontiers in physiology2026
Susceptibility to mild and severe acute mountain sickness is associated with distinct urine metabolite profiles.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid ascent to high altitude (HA) in unacclimatized lowlanders elicits a series of hematologic, ventilatory, metabolic, and cardiovascular adaptations to counteract the lower partial pressure of oxygen. When ascent occurs faster than the body can acclimatize, high-altitude illnesses (HAIs) can occur. The most prevalent of the HAIs is acute mountain sickness (AMS), which can range in severity from mild (minor inconvenience) to severe (total incapacitation). Symptoms of AMS include headache, fatigue, gastrointestinal distress, dizziness, and in some cases sleep disturbances. Identifying individuals at risk for severe AMS, prior to their ascent to HA, would be useful to initiate appropriate prophylaxis approaches in those individuals prior to ascent. We previously reported eight urinary metabolites, measured prior to HA exposure, that discriminated individuals susceptible to moderate or severe AMS from those resistant to AMS (NoAMS). These metabolites include creatine, acetylcarnitine, 3-methylhistidine, N-methylhistidine, hypoxanthine, 1-methylnicotinamide, taurine, and 4-hydroxyphenylpyruvate. This follow-on study examined 41 unacclimatized, physically active healthy soldiers (mean ± SD; age=26 ± 5yr) who were tested at their baseline residence (BLR, 331 m), transported to Taos, NM (2845 m), then immediately hiked (active ascent; n=21) or were driven (passive ascent; n=20) to a HA (3600 m) facility where they resided for four days. AMS was assessed using the shortened version of the Environmental Symptoms Questionnaire (ESQ) and AMS-C scores were calculated. Participants were categorized into resistant (NoAMS; AMS-C< 0.7), mild AMS (mAMS; AMS-C ≥0.7 but <1.53), and moderate to severe AMS (sAMS; AMS-C ≥1.53) groups. Urine samples collected at BLR and HA were analyzed using proton nuclear magnetic resonance (NMR) spectroscopy. BLR urinary metabolite profiles were significantly different (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.